Wedbush Maintains Neutral on Replimune Group, Raises Price Target to $9
Wedbush analyst Robert Driscoll maintains Replimune Group (NASDAQ: REPL ) with a Neutral and raises the price target from $6 to $9.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.